# Adaptive COVID-19 Treatment Trial 2 (ACTT-2)

> **NCT04401579** · PHASE3 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 1033 (actual)

## Conditions studied

- COVID-19

## Interventions

- **OTHER:** Placebo
- **DRUG:** Remdesivir
- **DRUG:** Baricitinib

## Key facts

- **NCT ID:** NCT04401579
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-08
- **Primary completion:** 2020-07-31
- **Final completion:** 2020-07-31
- **Target enrollment:** 1033 (ACTUAL)
- **Last updated:** 2022-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04401579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04401579, "Adaptive COVID-19 Treatment Trial 2 (ACTT-2)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04401579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*